Subscribe To

Price Alert Latest News Economic Calendar News

AGNPF / Algernon Pharma says unit completes dosing of first cohort in its Phase 1 clinical study of an intravenous formulation of DMT

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 (N,N-Dimethyltryptamine or DMT), a known psychedelic compound that is part of the tryptamine family. AGN Neuro also reported that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues. Read More

Demo Live Account See Partner Details

Content Topics

Algernon

Pharma

Says

Unit

Completes

Dosing

First

Cohort

Clinical

Intravenous

Formulation

Stock

AGNPF

Posted: Feb 16 2023, 07:59

Author Name: Proactive Investors

AGNPF News

By Proactive Investors
June 27, 2023

Algernon Pharma considers potential spin-off of its chronic cough research program

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has said it is considering the potential spin-off of its NP-120 (Ifenprodil) chronic cough resea

By Proactive Investors
June 5, 2023

Algernon Pharmaceuticals subsidiary completes DMT escalating dose study

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the th

By Proactive Investors
May 31, 2023

Algernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for Repirinast

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the Japanese Patent Office (JPO) for a patent ap

By Proactive Investors
April 17, 2023

Algernon Pharma receives Notice of Allowance from US Patent and Trademark Office for Repirinast

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the United States Patent and Trademark Office (US

By Proactive Investors
April 4, 2023

Algernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical study

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has completed dosing of the second cohort

By Proactive Investors
April 3, 2023

Algernon Pharma says wholly-owned subsidiary's Reg A+ offering gets US SEC qualification

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its wholly-owned subsidiary, Algernon NeuroScience (AGN Neuro), has qualified its Form 1-A o

By Proactive Investors
March 21, 2023

Algernon Pharmaceuticals to raise $2.4M by way of rights offering

Algernon Pharmaceuticals Inc announced that it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747. The Canadian clin

By Proactive Investors
March 2, 2023

Former NFL neurologist joins Algernon's program using DMT to treat traumatic brain injury

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has engaged Dr David Brody, an expert neurologist, as a consultant to support the company's clini

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.